Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32-1 - AIM ImmunoTech Inc. | s102655_ex32-1.htm |
| EX-31.2 - EXHIBIT 31-2 - AIM ImmunoTech Inc. | s102655_ex31-2.htm |
| EX-23.1 - EXHIBIT 23-1 - AIM ImmunoTech Inc. | s102655_ex23-1.htm |
| EX-31.1 - EXHIBIT 31-1 - AIM ImmunoTech Inc. | s102655_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - AIM ImmunoTech Inc. | s102655_ex21-1.htm |
| 10-K - FORM 10-K - AIM ImmunoTech Inc. | s102655_10k.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Hemispherx Biopharma, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas K. Equels, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| /s/ Adam Pascale | |
| Adam Pascale | |
| Chief Financial Officer | |
| March 29, 2016 |